TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03210857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: apnea performing
Description: The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made.
Study: NCT02255669

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: partially covered SEMS
Description: Used for palliation of inoperable malignant distal bile duct obstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fully covered SEMS
Description: Used for palliation of inoperable malignant distal bile duct obstruction.
Study: NCT01944696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phototherapy
Description: Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
Study: NCT02283385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT
Description: 8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
Study: NCT00970970

Intervention type: OTHER
Intervention: 89Zr bevacizumab PET scan
Description: Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
Study: NCT04642443

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSE Device
Description: The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENSE Device
Description: The SENSE Device is indicated for the monitoring of intracranial hemorrhage by detecting a suspected increase in blood volume within the cranial vault. It is an adjunctive device to the clinical evaluation in the acute hospital setting of patients 22 years of age or older with suspected or known intracranial hemorrhage. The device is indicated for use to monitor patients for intracranial hemorrhage expansion between CT scans but should not serve as a substitute for these scans.
Study: NCT00363883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03736447

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101 powder provided in capsules & sachets
Description: Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder provided in capsules & sachets
Description: Study product formulated to contain only inactive ingredients for use as defined in the protocol
Study: NCT02521545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB061
Description: Capsule
Study: NCT04141488

Intervention type: OTHER
Group type: OTHER
Intervention: experimantal group
Description: Control Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimantal group
Description: Control Group
Study: NCT04399317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow controlled ventilation (Evone-ventilator)
Description: The new ventilation technique will be applied
Study: NCT00737685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, fludarabine , thymoglobulin
Description: cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 \& -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 \& -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 \& -1)
Study: NCT02016729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 232
Description: Given an an oral tablet in escalating doses.
Study: NCT02861287

Intervention type: OTHER
Intervention: Economic evaluation
Study: NCT02016729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an oral tablet given in a fixed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib is an oral tablet given in a fixed dose.
Study: NCT03696940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Description: Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
Study: NCT01593228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550/BSI-201)
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCL liposome injection
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Pharmaceutical form:Solution~Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Pharmaceutical form:Solution~Route of administration: Intravenous
Study: NCT03461432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
Study: NCT01371448

Intervention type: DRUG
Intervention: Paroxetine
Study: NCT03457311

Intervention type: DRUG
Group type: OTHER
Intervention: G.S.P. Oral Solution 400 mg/ml
Description: Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
Study: NCT03628521

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
Description: Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
Description: Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
Description: Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
Study: NCT01398527

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educ sessions & LTC Osteoporosis toolkit
Description: Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
Study: NCT02473835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity monitoring
Description: For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet monitoring
Description: For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
Study: NCT03234972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
Study: NCT00663598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Treatment according to US PI
Study: NCT01743885

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acebutolol
Description: 10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propanolol
Description: 3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
Study: NCT02790710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol
Description: Active treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02451033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard medical therapy
Description: diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: Growth Hormone in low dose of 1unit sc daily for 1 year
Study: NCT03468049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical App. of Allium Cepa Extract
Description: Topical Application of Allium Cepa Extract (oil)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phonophoresis of Allium Cepa Extract
Description: Phonophoresis of Allium Cepa Extract (oil)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raw Mashed Allium Cepa Application
Description: Raw Allium Cepa (onion bulb) Mashed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Group (SPG)
Description: This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Group (SPG)
Description: This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Group (SPG)
Description: This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Group (SPG)
Description: This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
Study: NCT01892644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venesection
Description: Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
Study: NCT01860963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Pap smear and HPV DNA testing
Description: Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Pap smear and HPV DNA testing
Description: Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal Pap smear and HPV DNA testing
Description: Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
Study: NCT02182297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02707679

Intervention type: OTHER
Group type: OTHER
Intervention: Mulligan's Straight leg-raise with traction
Description: Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Mulligan's Mobilization with Movement
Description: Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
Study: NCT04300387

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary care
Description: multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
Study: NCT05858177

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide capsule
Description: Temozolomide was given orally per day for 5 days, every 28 days until disease progression or intolerable toxicities.
Study: NCT00593632

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Uncle Sam Cereal
Description: two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
Study: NCT04549935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextenza
Description: Dextenza 0.4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Prednisolone
Description: Standard of care topical drop treatment
Study: NCT01032018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline, citalopram, or bupropion
Description: Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Participants will receive standard of care from the current physicians
Study: NCT04363840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg to be taken orally once daily for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Aspirin 81 mg to be taken orally once daily for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 50,000 IU to be taken orally once weekly for 2 weeks
Study: NCT03664895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuplin or zoladex
Description: OFS(Leuplin or zoladex) add on to TMX
Study: NCT04524052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscularly injection at pre-defined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscularly injection at pre-defined injection sites
Study: NCT01968694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV diphenhydramine
Study: NCT00982176

Intervention type: OTHER
Intervention: Brain MRI and cerebral perfusion scintigraphy
Description: A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide.
Study: NCT01011244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADIPOPLUS
Description: autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula
Study: NCT01857960

Intervention type: BEHAVIORAL
Intervention: Survey
Description: A survey is directly applied to subjects who meet the inclusion and exclusion criteria